Publication:
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

dc.contributor.authorSchettini, Francesco
dc.contributor.authorGiuliano, Mario
dc.contributor.authorLambertini, Matteo
dc.contributor.authorBartsch, Rupert
dc.contributor.authorPinato, David James
dc.contributor.authorOnesti, Concetta Elisa
dc.contributor.authorHarbeck, Nadia
dc.contributor.authorLüftner, Diana
dc.contributor.authorRottey, Sylvie
dc.contributor.authorvan Dam, Peter A.
dc.contributor.authorZaman, Khalil
dc.contributor.authorMustacchi, Giorgio
dc.contributor.authorGligorov, Joseph
dc.contributor.authorAwada, Ahmad
dc.contributor.authorCampone, Mario
dc.contributor.authorWildiers, Hans
dc.contributor.authorGennari, Alessandra
dc.contributor.authorTjan-Heijnen, Vivianne C. G.
dc.contributor.authorCortes, Javier
dc.contributor.authorLocci, Mariavittoria
dc.contributor.authorParis, Ida
dc.contributor.authorDel Mastro, Lucia
dc.contributor.authorDe Placido, Sabino
dc.contributor.authorMartín Jiménez, Miguel José
dc.contributor.authorJerusalem, Guy
dc.contributor.authorVenturini, Sergio
dc.contributor.authorCurigliano, Giuseppe
dc.contributor.authorGenerali, Daniele
dc.date.accessioned2023-06-16T14:20:39Z
dc.date.available2023-06-16T14:20:39Z
dc.date.issued2021-09-01
dc.description.abstractAnthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first-line phase III trials in HER2-negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2-negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/70888
dc.identifier.doi10.3390/cancers13174421
dc.identifier.issn2072-6694
dc.identifier.officialurlhttps://doi.org/10.3390/cancers13174421
dc.identifier.relatedurlhttps://www.mdpi.com/2072-6694/13/17/4421/htm
dc.identifier.urihttps://hdl.handle.net/20.500.14352/4754
dc.issue.number17
dc.journal.titleCancers
dc.language.isoeng
dc.page.initial4421
dc.publisherMPDI
dc.rightsAtribución 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/es/
dc.subject.keywordanthracyclines
dc.subject.keywordbreast cancer
dc.subject.keywordtriple negative
dc.subject.keywordhormone receptor
dc.subject.keywordmetastatic
dc.subject.keywordnon-pegylated liposomal doxorubicin
dc.subject.ucmEndocrinología
dc.subject.ucmOncología
dc.subject.unesco3205.02 Endocrinología
dc.subject.unesco3201.01 Oncología
dc.titleAnthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
dc.typejournal article
dc.volume.number13
dspace.entity.typePublication
relation.isAuthorOfPublication15312355-7a09-495e-a1a2-32e8be5259c3
relation.isAuthorOfPublication.latestForDiscovery15312355-7a09-495e-a1a2-32e8be5259c3
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
cancers-13-04421-v2.pdf
Size:
1.18 MB
Format:
Adobe Portable Document Format
Collections